Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.

View in: PubMed

subject areas

Aged
Alkaline Phosphatase
Biomarkers
Cardiovascular Diseases
Clinical Trials, Phase II as Topic
Comorbidity
Dose-Response Relationship, Drug
Down-Regulation
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Quinazolinones
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome

authors with profiles

Kamyar Kalantar-Zadeh M.D., MD, PhD